Cardiomyopathy associated with anti-SARS-CoV-2 vaccination: What do we know?
Access noteAcceso abierto
MetadataShow full item record
The SARS-CoV-2 pandemic has mobilized many efforts worldwide to curb its impact on morbidity and mortality. Vaccination of the general population has resulted in the administration of more than 6,700,000,000 doses by the end of October 2021, which is the most effective method to prevent hospitalization and death. Among the adverse effects described, myocarditis and pericarditis are low-frequency events (less than 10 per 100,000 people), mainly observed with messenger RNA vaccines. The mechanisms responsible for these effects have not been specified, considering an exacerbated and uncontrolled immune response and an autoimmune response against specific cardiomyocyte proteins. This greater immunogenicity and reactogenicity is clinically manifested in a differential manner in pediatric patients, adults, and the elderly, determining specific characteristics of its presentation for each age group. It generally develops as a condition of mild to moderate severity, whose symptoms and imaging findings are self-limited, resolving favorably in days to weeks and, exceptionally, reporting deaths associated with this complication. The short- and mediumterm prognosis is favorable, highlighting the lack of data on long-term evolution, which should be determined in longer follow-ups.
Artículo de publícación WoSArtículo de publicación SCOPUS
Quote ItemViruses 2021, 13, 2493.
The following license files are associated with this item: